<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Sch of Biosciences</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9729A4DB-2FB1-40BC-8B89-E8FA153AD4C2"><gtr:id>9729A4DB-2FB1-40BC-8B89-E8FA153AD4C2</gtr:id><gtr:firstName>Gurdyal Singh</gtr:firstName><gtr:surname>Besra</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C729E8DE-F8AA-4EAD-9C0D-78FA2F948D3F"><gtr:id>C729E8DE-F8AA-4EAD-9C0D-78FA2F948D3F</gtr:id><gtr:firstName>David Ernest</gtr:firstName><gtr:surname>Minnikin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/DC56C359-8F37-4BAF-B2E4-8C55DC097D1A"><gtr:id>DC56C359-8F37-4BAF-B2E4-8C55DC097D1A</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Anthony</gtr:otherNames><gtr:surname>Lammas</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A0AFA01E-00C0-4C35-8FC9-2DB108656028"><gtr:id>A0AFA01E-00C0-4C35-8FC9-2DB108656028</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Richard</gtr:otherNames><gtr:surname>Barer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G9901077"><gtr:id>9125A5BE-2B19-49DB-B583-26AF47F42AA1</gtr:id><gtr:title>MAGPIE Project: The Structure, Biosynthesis and Assembly of the Mycobacterial Cell Envelope</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9901077</gtr:grantReference><gtr:abstractText>Tuberculosis (TB) is a life ?threatening condition that can last for several years during which patients are debilitated and may disseminate the bacterium that causes the disease, Mycobacterium tuberculosis (Mtb). At least 30 million individuals worldwide will have died from TB in the last decade of the 20th century. In the UK the steady decline in TB cases over the whole of the last century halted in the mid 1980s and there has been alarming signs of increased numbers of cases in certain communities. The situation is compounded by the AIDS epidemic and by the emergence of Mtb strains that are resistant to virtually all the drugs that would normally be used to treat TB. It can be argued that, globally, Mtb is the single most important infectious agent affecting mankind. All bacteria have cells that, like plants, are enclosed in a cell wall. This protects the organism from its immediate environment and, fortuitously, presents an important target for drugs, like penicillin, that can be used to treat bacterial infections. However, Mtb has a distinctive cell wall that differs in composition from that of other bacteria; in particular it contains an exceptional amount of unique lipids (fats) and sugars. Although there are drugs that affect the unique Mtb cell wall, the current treatment for tuberculosis lasts 6 months and is potentially toxic to patients who often cease treatment early. Moreover, the efficacy of treatment is threatened by the emergence of drug-resistant strains of Mtb. There is therefore a great need for new and better drugs to treat TB. In this coordinated set of projects, the investigators are combining their particular expertise in analysing the Mtb cell wall to improve our understanding of these remarkable structures and the metabolic processes that are required for their assembly.

Communication to the general public will be channelled through the University Press Office at Birmingham (http://www.newscentre.bham.ac.uk/office.htm) and Leciester (http://www.le.ac.uk/press/), which have established contacts in the local and national media. The MRC Co-operative Group members will also highlight there research through personal University based Web pages, which has open access. This highlights the clinical and research elements of the MRC Co-operative Group.</gtr:abstractText><gtr:technicalSummary>The Mycolyl-Arabinogalactan-Peptidoglycan Initiative and Exploitation (MAGPIE) project is aimed at coordinating a continued integrated investigation and exploitation of the basic physiology of the mycolyl-arabinogalactan-peptidoglycan complex and associated free lipids in the cell envelope of Mycobacterium tuberculosis. Mycolic acids are essential envelope components and key drug targets; substantial current progress will be vigorously continued into understanding the enzymology of mycolate synthesis, particularly for condensing and tranferase enzymes. New drugs, targeting mycolate-condensing enzymes, will be synthesized, tested and new analogues developed. Mycolates are supported on an arabinogalactan, linked to the basal wall peptidoglycan; the glycosyltransferases involved in the assembly of this complex matrix will continue to be characterised, as will the related enzymes leading to the prime envelope lipoarabinomannan immunogen. A range of characteristic waxes and antigenic acylated trehalose glycolipids are expressed on the cell surface and the detailed immunology and pathogenic role of these will be unravelled. The expression of cell envelope components in the M. tuberculosis complex, in vivo and in vitro, will be studied, using sensitive methods which will also continue to be applied to the detection of ancient and modern disease. The role of human CD1 recognition systems will be exhaustively explored, revealing innovative directions for the treatment or prevention of tuberculosis. All of the above prime investigations will exploit the full power of modern genomics, as will new areas being developed, such as the role of P450 enzymes, N-acetyl transferases, siderophores and phosphatidylinositol-based lipoglycans from related mycolata taxa.</gtr:technicalSummary><gtr:fund><gtr:end>2011-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2000-08-14</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>915915</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>New TB drugs?</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>AD161ADB-6D91-483A-B3AC-88C9FF58290E</gtr:id><gtr:impact>Interview and presentation for the BBC Inside Out

None</gtr:impact><gtr:outcomeId>D491B41401A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BCG Vaccine and problems?</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>807243FC-FDD3-4D47-B618-B38297A77A08</gtr:id><gtr:impact>BBC Inside Out

None</gtr:impact><gtr:outcomeId>0EBFE84C19D</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New TB drugs and vaccines?</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F40AE8FE-8F70-49A2-A4E4-D1E33CE2703E</gtr:id><gtr:impact>Interview with the BBC and Inside Out Show for the West Midlands.

None</gtr:impact><gtr:outcomeId>DF6B35BD584</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>28FD0E03-ABC5-49A0-A54A-F497D0386013</gtr:id><gtr:impact>Interview and presentation on vaccines and new drug targets

None</gtr:impact><gtr:outcomeId>E001FED08EB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New TB drug targets and vaccines</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>637FF959-D5BB-4FA3-BEAE-C639CB0DD2C4</gtr:id><gtr:impact>An interview with the BBC Inside Out show.

None</gtr:impact><gtr:outcomeId>4652622D6AE</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New TB Drugs</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BED6F61A-2BF7-4FAC-B7DC-81B0DA7D6E2B</gtr:id><gtr:impact>Interview for BBC Inside Out.

None</gtr:impact><gtr:outcomeId>57DE7FE480A</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>478000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>B7531AFB-6A91-49A4-8545-2349114B2976</gtr:id><gtr:outcomeId>BFD5C6EB6360</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>420000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2009-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>346136E5-3439-42E3-80A9-0567AE4CEE37</gtr:id><gtr:outcomeId>60FF17BAD9C0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>246000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRc Research Grant</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E1272B9F-A2C9-4BB1-8B14-DE08D77D54F4</gtr:id><gtr:outcomeId>519C3799ECF0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>316000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2011-02-02</gtr:end><gtr:fundingOrg>European Respiratory Society (ERS)</gtr:fundingOrg><gtr:id>EDF4F1B7-2827-4833-91F6-DE6BD81EAEFC</gtr:id><gtr:outcomeId>6629118F81C0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>257854</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Newton Fund</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>A20C0AE5-D27D-46A6-BBAD-04374BF0A041</gtr:id><gtr:outcomeId>569f709ec56990.79493940</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>455000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BBSRC Research Grant</gtr:description><gtr:end>2010-12-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>2BDD4BE4-F03D-48D5-8694-DC930E0B2123</gtr:id><gtr:outcomeId>7FBA1FEB0720</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>505000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant</gtr:description><gtr:end>2013-05-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>14D4D1A9-0345-46F4-92EF-C98235C96729</gtr:id><gtr:outcomeId>613B615AC260</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>569402</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Programme Grant (Novel invariant NKT cell agonists as adjuvants for antigen specific T and B cell responses)</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>6C330EF0-71F4-4C35-930F-F16A98BD11D5</gtr:id><gtr:outcomeId>528530F265B0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1226535</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Programme Grant (An integrated multi-disciplinary approach to unravel complex and essential cell wall biosynthetic pathways involved in arabinogalactan and lipoarabinomannan assembly in Mycobacterium tuberculosis)</gtr:description><gtr:end>2012-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>017CACA4-FB11-48DF-94C8-0585427A3B36</gtr:id><gtr:outcomeId>A88210C69AC0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>476000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant</gtr:description><gtr:end>2009-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>4783664B-470C-49F9-A195-C9462CD07653</gtr:id><gtr:outcomeId>5D75B618D050</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>330000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Co-operative Group Grant</gtr:description><gtr:end>2011-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9B0D7028-01A9-41C9-8EEA-EBA30F74A977</gtr:id><gtr:outcomeId>C67AC5C20AD0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Synthesis of a new analogue termed threitol ceramide</gtr:description><gtr:grantRef>G9901077</gtr:grantRef><gtr:id>D2F79586-FFE2-4C56-9A3D-5A2F40E59C27</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>DECF8CE4DDA</gtr:outcomeId><gtr:patentId>WO2007050668</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Analogs of a-galactosylceramide and uses thereof</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A NP-derivative of galactosyl ceramide for cross talk between NKT and B cells</gtr:description><gtr:grantRef>G9901077</gtr:grantRef><gtr:id>6C7043AA-14D9-4D27-BDA3-ADBDA1EAD8D9</gtr:id><gtr:impact>None</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>DCB09A0B6A0</gtr:outcomeId><gtr:patentId>WO2007051004?</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Conjugate vaccines for non-proteinaceous antigens.</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>New derivatives of galactosyl ceramide to promote Th1 responses, and cross-talk between NKT and B cells</gtr:description><gtr:id>BE8D770A-9701-4A3D-86D9-05D816793827</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>BEC79DC4369</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>galactosyl ceramide derivatives</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2CFDC7B0-C42F-451D-A65D-8659274E903D</gtr:id><gtr:title>Identification of a novel alpha(1--&amp;gt;6) mannopyranosyltransferase MptB from Corynebacterium glutamicum by deletion of a conserved gene, NCgl1505, affords a lipomannan- and lipoarabinomannan-deficient mutant.</gtr:title><gtr:parentPublicationTitle>Molecular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1764466a9db2af8c2be90c94ee57fb4e"><gtr:id>1764466a9db2af8c2be90c94ee57fb4e</gtr:id><gtr:otherNames>Mishra AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0950-382X</gtr:issn><gtr:outcomeId>003B6EA503F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>182D9123-EA68-4BD2-9713-377DC7F5B766</gtr:id><gtr:title>The role of hydrophobicity in tuberculosis evolution and pathogenicity.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f60c93dbae3971fabdf37e87ae5639f4"><gtr:id>f60c93dbae3971fabdf37e87ae5639f4</gtr:id><gtr:otherNames>Jankute M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa6641400d6b4.34638495</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E115D02-B4E4-4E70-B750-977BF7DC1C74</gtr:id><gtr:title>Tb Airborne Transmission: First Gene Expression Signatures Of Captured, Uncultured M. Tuberculosis From Human Source Aerosol</gtr:title><gtr:parentPublicationTitle>AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2d06eda41aba96b9eda90119962f2ed"><gtr:id>f2d06eda41aba96b9eda90119962f2ed</gtr:id><gtr:otherNames>Nardell E. A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-449X</gtr:issn><gtr:outcomeId>58bd666d814f62.40330435</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7ED18DE5-F391-45DE-98A9-DED0BA260864</gtr:id><gtr:title>Mannan chain length controls lipoglycans signaling via and binding to TLR2.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f1c9aa4c0f3f386f852ceb795b757e8"><gtr:id>9f1c9aa4c0f3f386f852ceb795b757e8</gtr:id><gtr:otherNames>Nigou J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>6666C97A3F1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E7A15EF-A81B-4399-AF2D-90336163592E</gtr:id><gtr:title>The condensing activities of the Mycobacterium tuberculosis type II fatty acid synthase are differentially regulated by phosphorylation.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3505e1a5535436aaefa3e598fad5278"><gtr:id>e3505e1a5535436aaefa3e598fad5278</gtr:id><gtr:otherNames>Molle V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>1F57D7F9178</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B28F1712-F154-4F61-A563-D86565DEDE19</gtr:id><gtr:title>Characterization of the putative operon containing arylamine N-acetyltransferase (nat) in Mycobacterium bovis BCG.</gtr:title><gtr:parentPublicationTitle>Molecular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6303f7ec7f90ffbd3ed5499782c07a45"><gtr:id>6303f7ec7f90ffbd3ed5499782c07a45</gtr:id><gtr:otherNames>Anderton MC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0950-382X</gtr:issn><gtr:outcomeId>9AFFC425B33</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EDB41FA-ADE6-41C0-8DBA-BD9B07B2713F</gtr:id><gtr:title>Alteration of the relative levels of iNKT cell subsets is associated with chronic mycobacterial infections.</gtr:title><gtr:parentPublicationTitle>Clinical immunology (Orlando, Fla.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9eda599b4896f2b981d5bdb5f92f960f"><gtr:id>9eda599b4896f2b981d5bdb5f92f960f</gtr:id><gtr:otherNames>Im JS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1521-6616</gtr:issn><gtr:outcomeId>F66372730EA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7916C5F-11C2-45A7-B5B0-9DA30FB25733</gtr:id><gtr:title>Synthesis of deoxygenated alpha(1--&amp;gt;5)-linked arabinofuranose disaccharides as substrates and inhibitors of arabinosyltransferases of Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/129e6a7d89b1eeef536815288f3004e2"><gtr:id>129e6a7d89b1eeef536815288f3004e2</gtr:id><gtr:otherNames>Pathak AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0968-0896</gtr:issn><gtr:outcomeId>1D9E5306C84</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F53A1824-6BF6-48EE-8658-158D4FDD37FA</gtr:id><gtr:title>EmbR2, a structural homologue of EmbR, inhibits the Mycobacterium tuberculosis kinase/substrate pair PknH/EmbR.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3505e1a5535436aaefa3e598fad5278"><gtr:id>e3505e1a5535436aaefa3e598fad5278</gtr:id><gtr:otherNames>Molle V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>745E317996A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7E51236-0327-4C1F-A9EC-A0BCD005A12C</gtr:id><gtr:title>Synthesis and biological evaluation of a C5-biphenyl thiolactomycin library.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/749291bc8fb7017a50d46025281050b0"><gtr:id>749291bc8fb7017a50d46025281050b0</gtr:id><gtr:otherNames>Bhowruth V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>7BDE46A80FE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9E09955-218D-43C5-A5AD-65F3D997B44B</gtr:id><gtr:title>Structure of the diaminopimelate epimerase DapF from Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Acta crystallographica. Section D, Biological crystallography</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/286e637dccc3e05c93cc3ebe3583bb1c"><gtr:id>286e637dccc3e05c93cc3ebe3583bb1c</gtr:id><gtr:otherNames>Usha V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0907-4449</gtr:issn><gtr:outcomeId>A154FEFB37A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BAF8DE8-A816-420C-9DCE-D98EF99548B5</gtr:id><gtr:title>Serum lipids regulate dendritic cell CD1 expression and function.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/519f746753369cc65826abb92db39d4e"><gtr:id>519f746753369cc65826abb92db39d4e</gtr:id><gtr:otherNames>Leslie DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>DFCD9B19871</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A6ACD26B-A5E5-44A7-993E-CD024399E196</gtr:id><gtr:title>Glycosylation of the phosphate binding protein, PstS, in Streptomyces coelicolor by a pathway that resembles protein O-mannosylation in eukaryotes.</gtr:title><gtr:parentPublicationTitle>Molecular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/218de1268990faf7089097ab1243eddc"><gtr:id>218de1268990faf7089097ab1243eddc</gtr:id><gtr:otherNames>Wehmeier S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0950-382X</gtr:issn><gtr:outcomeId>6F20F48FAF0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD9B5227-65AD-448A-A318-8B32BB91BA43</gtr:id><gtr:title>Molecular structure of EmbR, a response element of Ser/Thr kinase signaling in Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/938585ac20ff7a91cc730466157b3634"><gtr:id>938585ac20ff7a91cc730466157b3634</gtr:id><gtr:otherNames>Alderwick LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>BBBFA6585B0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5EBBD9D-33E9-4415-AA42-EF1DAB47E09B</gtr:id><gtr:title>Sequence and analysis of a plasmid-encoded mercury resistance operon from Mycobacterium marinum identifies MerH, a new mercuric ion transporter.</gtr:title><gtr:parentPublicationTitle>Journal of bacteriology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1188c81f410f0c43e1a7338aa651bdda"><gtr:id>1188c81f410f0c43e1a7338aa651bdda</gtr:id><gtr:otherNames>Schu? M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9193</gtr:issn><gtr:outcomeId>36704500051</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>669C550F-569C-4B82-9161-FBAF8D5F7102</gtr:id><gtr:title>The 5-deoxy-5-methylthio-xylofuranose residue in mycobacterial lipoarabinomannan. absolute stereochemistry, linkage position, conformation, and immunomodulatory activity.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ffff64d8a2ed3dad31667dc5b54e029"><gtr:id>8ffff64d8a2ed3dad31667dc5b54e029</gtr:id><gtr:otherNames>Joe M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn><gtr:outcomeId>06EC8E0FFD6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A02F6599-C0E8-467B-8BFB-204CCD448433</gtr:id><gtr:title>Arabinan-deficient mutants of Corynebacterium glutamicum and the consequent flux in decaprenylmonophosphoryl-D-arabinose metabolism.</gtr:title><gtr:parentPublicationTitle>Glycobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/938585ac20ff7a91cc730466157b3634"><gtr:id>938585ac20ff7a91cc730466157b3634</gtr:id><gtr:otherNames>Alderwick LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0959-6658</gtr:issn><gtr:outcomeId>59990A33FF8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1A85560-8C1C-41CF-9D26-E3800EB3BC48</gtr:id><gtr:title>Exploring the substrate specificity of a mycobacterial polyprenol monophosphomannose-dependent alpha-(1--&amp;gt;6)-mannosyltransferase.</gtr:title><gtr:parentPublicationTitle>Chembiochem : a European journal of chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a748ed181dea7131316f61fbe308179c"><gtr:id>a748ed181dea7131316f61fbe308179c</gtr:id><gtr:otherNames>Tam PH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1439-4227</gtr:issn><gtr:outcomeId>4999967FD1B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6CF6773D-4840-406B-88B7-67DEE62DA732</gtr:id><gtr:title>Structural characterization and functional properties of a novel lipomannan variant isolated from a Corynebacterium glutamicum pimB' mutant.</gtr:title><gtr:parentPublicationTitle>Antonie van Leeuwenhoek</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1764466a9db2af8c2be90c94ee57fb4e"><gtr:id>1764466a9db2af8c2be90c94ee57fb4e</gtr:id><gtr:otherNames>Mishra AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0003-6072</gtr:issn><gtr:outcomeId>43FC9949164</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7789174-E5DA-42DE-ABA2-EB0BF3AA7593</gtr:id><gtr:title>The mannose cap of mycobacterial lipoarabinomannan does not dominate the Mycobacterium-host interaction.</gtr:title><gtr:parentPublicationTitle>Cellular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eda33d4172c55d2b2453840683890ad1"><gtr:id>eda33d4172c55d2b2453840683890ad1</gtr:id><gtr:otherNames>Appelmelk BJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1462-5814</gtr:issn><gtr:outcomeId>C59A8464F12</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59318F6A-A06A-4F85-B531-39A35E52ECCE</gtr:id><gtr:title>Characterization of Mycobacterium tuberculosis diaminopimelic acid epimerase: paired cysteine residues are crucial for racemization.</gtr:title><gtr:parentPublicationTitle>FEMS microbiology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/286e637dccc3e05c93cc3ebe3583bb1c"><gtr:id>286e637dccc3e05c93cc3ebe3583bb1c</gtr:id><gtr:otherNames>Usha V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0378-1097</gtr:issn><gtr:outcomeId>273AC0ECC7F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF297845-F4FD-42A9-9F86-03D58E2BE9CF</gtr:id><gtr:title>Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74aaa8e47112a3ae798b15a63c7ab34e"><gtr:id>74aaa8e47112a3ae798b15a63c7ab34e</gtr:id><gtr:otherNames>Guillonneau C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>6FBA82E87A8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9205E80-E004-4B2C-8B30-D2667F854688</gtr:id><gtr:title>Antimycobacterial Activity and Mechanism of Action of NAS-91.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2491440f8a6c62e939c99571a7a4fa0c"><gtr:id>2491440f8a6c62e939c99571a7a4fa0c</gtr:id><gtr:otherNames>Gratraud P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>37864C555CF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>85261120-E587-44C4-9A66-2CD7FB1F2B1D</gtr:id><gtr:title>Use of a codon alteration strategy in a novel approach to cloning the Mycobacterium tuberculosis diaminopimelic acid epimerase.</gtr:title><gtr:parentPublicationTitle>FEMS microbiology letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/286e637dccc3e05c93cc3ebe3583bb1c"><gtr:id>286e637dccc3e05c93cc3ebe3583bb1c</gtr:id><gtr:otherNames>Usha V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0378-1097</gtr:issn><gtr:outcomeId>03CAE5329BE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C71F3FD-B3EE-41B8-91C7-2E9F4F028FD3</gtr:id><gtr:title>Self-poisoning of Mycobacterium tuberculosis by targeting GlgE in an alpha-glucan pathway.</gtr:title><gtr:parentPublicationTitle>Nature chemical biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1b2c58e57e9ab1ad2c24e9a9f0d3183"><gtr:id>a1b2c58e57e9ab1ad2c24e9a9f0d3183</gtr:id><gtr:otherNames>Kalscheuer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1552-4450</gtr:issn><gtr:outcomeId>o6aijmVbm5W</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F95268C-BC9E-436E-8C49-D109B5CB354C</gtr:id><gtr:title>Tuberculosis: a balanced diet of lipids and carbohydrates.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/749291bc8fb7017a50d46025281050b0"><gtr:id>749291bc8fb7017a50d46025281050b0</gtr:id><gtr:otherNames>Bhowruth V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>43FD8130A2A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF173FCA-BD90-4300-A98A-E97C0ACCDC46</gtr:id><gtr:title>Identification of a novel arabinofuranosyltransferase (AftA) involved in cell wall arabinan biosynthesis in Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/938585ac20ff7a91cc730466157b3634"><gtr:id>938585ac20ff7a91cc730466157b3634</gtr:id><gtr:otherNames>Alderwick LJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>A91A9E6669A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F7CA538-23A6-4C74-AF9E-08DB49D3BF32</gtr:id><gtr:title>Trehalose-recycling ABC transporter LpqY-SugA-SugB-SugC is essential for virulence of Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1b2c58e57e9ab1ad2c24e9a9f0d3183"><gtr:id>a1b2c58e57e9ab1ad2c24e9a9f0d3183</gtr:id><gtr:otherNames>Kalscheuer R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>d2Bcm1aYFpF</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9901077</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>